Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Doctors & Hospitals

Doctronic Offers AI-Powered Prescription Drug Renewals for $4

Posted on March 12, 2026March 9, 2026 by Devon Herrick

I for one am not concerned about AI prescribing. I am concerned it has not yet reached Texas.

+

Tuesday Links – 10 March 2026

Posted on March 10, 2026March 9, 2026 by John C. Goodman
  • “By 2022, the US had one of the highest shares of primary care physicians reporting burnout (44 percent). Switzerland (18 percent) and the Netherlands (12 percent) had the lowest shares reporting.”
  • Some people 80 and up have the memory ability of someone 30 years younger. 
  • Moderna’s combo mRNA is effective against three main flu strains plus covid. Th’s Ok in Europe. But not for the FDA? (WSJ)
  • Last year’s job gains were due to heath care.
  • Chatbot psychosis is real. (WSJ)
  • Five leading AI models gave bad medical advice.
+

Saturday Links – 7 March 2026

Posted on March 7, 2026March 6, 2026 by John C. Goodman
  • Medical schools to start teaching MAHA approach to nutrition.
  • What to know about vaccine mandates, vaccine lawsuits and compensation for vaccine injuries.
  • Disappointment at TrumpRx: later, the site has only 44 of the 24,000 prescription drugs that federal regulators have approved.
  • If we defunded the police, could we have law enforcement without them?
  • More than 40 percent of heath care spending is for shoppable services.
+

The FDA is Increasingly Skeptical of Therapies for Rare Diseases

Posted on March 7, 2026March 6, 2026 by Devon Herrick

The FDA under Trump has consistently maintained its stated goal of removing bureaucratic obstacles to drug approval. FDA commissioner, Marty Makary, announced steps to speed the approval of new drugs, including allowing one well-designed clinical trial rather than two or more trials to show efficacy. Yet, drug companies continue to claim inconsistent guidelines, endpoints changed and a skeptical agency when it comes to rare disease therapies. Recently drugmakers have complained the FDA moved the goalposts, after agreeing to them. 

+
  • Previous
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 207
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 44 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom